Anti-diabetes and obesity drug Mounjaro launched in India

Popular anti-diabetes and obesity drug Mounjaro has been launched in India, by the US-based pharmaceutical giant Eli Lilly, after receiving marketing authorisation from India's drug regulator - the Central Drugs Standard Control Organisation (CDSCO).

Mounjaro is used for type 2 diabetes or diabetes mellitus and weight management. The drug is now available in a single-dose vial that works by activating two key hormones, GIP and GLP-1, which help control blood sugar levels and appetite.

It is meant to be used along with a healthy diet and regular exercise. The prescription drug is recommended for:  1-Adults with obesity (BMI of 30 or more). 2-Adults who are overweight (BMI of 27 or more) and have other health problems related to weight. 3-Adults with type 2 diabetes to help manage blood sugar.

Obesity and type 2 diabetes are rising rapidly in India, making them major health challenges. Winslow Tucker, President of Lilly India, said the company is working with the government and healthcare industry to raise awareness and improve treatment options.

In July 2024, a subject expert committee under India's apex drug regulator, had given a green light to Lilly's tirzepatide, the active ingredient in their popular drugs Mounjaro and Zepbound.

Since Mounjaro (tripetide) is a prescription-based drug, the treatment plan is determined by a healthcare professional and varies for each individual. However, at the starting dose of 2.5 mg, the monthly price would be Rs 14,000. A single-dose vial of 2.5 mg is priced at Rs 3,500, and the 5 mg injection cost Rs 4,375.

Dr. Manish Mistry, Senior Medical Director at Eli Lilly India, highlighted the importance of effective treatment. "Obesity and diabetes can cause serious health problems, so we need strong, long-term solutions. Mounjaro offers a new way to manage these conditions," he said. The launch of Mounjaro in India provides a new option for patients and doctors looking for effective treatment.